Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Oncological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CYP27B1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CYP27B1 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Optimized for enzymatic assays. |
View CYP27B1 Products |
| Gene Delivery | CYP27B1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and mitochondrial localization studies. |
View CYP27B1 Products |
| Benchmark Ab | Anti-CYP27B1 Recombinant Antibody Recombinant positive control for western blot and IHC validation. |
View CYP27B1 Products |
| Validator | CYP27B1 siRNA Set For knockdown verification in functional assays. |
View CYP27B1 Products |
| Related Target A | CYP24A1 Catabolic counterpart that inactivates calcitriol; critical for dual-targeting/selectivity assays. |
View CYP24A1 Products |
| Related Target B | VDR Vitamin D Receptor; downstream nuclear receptor mediating genomic actions of calcitriol. |
View VDR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mitochondrial membrane protein solubility | Optimized truncation and detergent-free solubilization protocols, sequence verified. |
| Subfamily counter screening (CYP24A1, CYP27A1) | Homolog panel proteins strictly verified by mass spectrometry to ensure no cross-reactivity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and sequence-verified positive controls included |
| False Positives | Validated siRNA sets included for target-specific knockdown verification |
Live CYP27B1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CYP27B1 therapeutics is intensifying, with major players shifting focus from traditional hormone replacement to small-molecule modulators and gene therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting tissue-specific CYP27B1 expression in the immune microenvironment and oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Modulators | Academic Medical Centers, Specialty Pharma | Hypercalcemia, Chronic Kidney Disease (CKD) | Enzymatic Activity Assay (Need high-purity, active recombinant CYP27B1) |
| Gene Therapy / mRNA | Rare Disease Biotechs | Vitamin D-Dependent Rickets Type 1A (VDDR1A) | Expression Validation (Need Lentivirus for stable cell line construction) |
| Immunotherapy Combinations | Oncology Biopharma | Solid Tumors (Tumor Microenvironment) | Selectivity Assay (Need CYP27B1 vs CYP24A1 mutant/WT protein panels) |